Espi Industries & Chemicals

What Espi Industries & Chemicals does

Espi Industries & Chemicals Pvt Ltd is a Hyderabad-based, family-owned contract pharmaceutical manufacturer founded in 1979 by Mr. Ashwini Chadda. The company specializes in oral liquid formulations — including syrups, suspensions, cough syrups, raft-formulation antacids (Instaraft Syrup and Raciraft Syrup), and sodium alginate products — and serves enterprise pharmaceutical clients such as Dr. Reddy's Laboratories, Pfizer, Sun Pharmaceuticals, Abbott India, Alembic, Intas, JB Chemicals, and Hetero Healthcare. Its 10,000 sq meter flagship manufacturing facility in Uppal, Hyderabad operates five oral liquid filling and packing lines with annual capacity of 70 million bottles, supported by a 5,000 sq ft GLP-approved research center, an analytical laboratory equipped with HPLC and AAS instruments, and six stability chambers. The company generates revenue through B2B contract manufacturing agreements negotiated on a quote basis, complemented by pharmaceutical development, analytical, and stability study services. Espi holds WHO-GMP certification (since 2013) and NAFDAC approval (since 2024), enabling exports to 17 African nations with active regulatory expansion into Russia and Southeast Asia. In 2025, Espi became the first SME in India to set Science Based Targets initiative (SBTi) approved GHG emissions reduction targets, achieving its 2023 decarbonization milestone ahead of schedule under a partnership with Sprih.

Name

Espi Industries & Chemicals

Legal name

Espi Industries & Chemicals Pvt Ltd

Website

https://espiindia.com

Company type

Private

Founded year

1979

Operating status

Operating

Headcount range

11–50 employees

Short description

Espi Industries & Chemicals is a Hyderabad-based contract pharmaceutical manufacturer specializing in oral liquid formulations, serving enterprise clients like Dr. Reddy's, Pfizer, and Sun Pharma from a WHO-GMP certified facility with 70 million bottle annual capacity.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG)

Keywords

• Pharmaceutical contract manufacturing
• Oral liquid formulations
• Antacid manufacturing
• Raft formulation technology
• Pharmaceutical development services

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: B2B contract pharmaceutical manufacturing services for oral liquid formulations. The company manufactures products for pharmaceutical clients including major brands like Pfizer, Sun Pharmaceuticals, Dr. Reddy's, Abbott, and others. Revenue generated through manufacturing contracts for specialized formulations including antacids, cough syrups, raft syrups, and other oral liquids.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Espi Industries & Chemicals is a B2B pharmaceutical contract manufacturer specializing in oral liquid formulations including antacid syrups (notably proprietary raft formulations such as Instaraft Syrup and Raciraft Syrup), cough syrups, suspensions, and sodium alginate syrups. The company manufactures these products on behalf of major pharmaceutical brands (Pfizer, Sun Pharmaceuticals, Abbott India, Dr. Reddy's, Alembic, Intas, JB Chemicals, Hetero Healthcare) and also offers integrated pharmaceutical development services, GLP-approved analytical testing, and stability studies to support client formulations from pre-formulation through commercial scale-up.

Product overview

Espi Industries & Chemicals is a contract pharmaceutical manufacturer specializing in specialized oral liquid formulations, operating as a single unified business organized around development and manufacturing services. The core product portfolio includes branded raft-formulation antacids such as Instaraft Syrup and Raciraft Syrup, alongside a broader range of oral liquids including syrups, suspensions, cough syrups, and Sodium Alginate syrups. These products are supported by integrated Pharmaceutical Development Services (covering pre-formulation, formulation, scale-up, and technical transfer), Analytical Capabilities Services (GLP-approved lab with HPLC, AAS, and microbiology testing), and Stability Studies Services. The company positions itself as a comprehensive contract manufacturing partner, primarily serving major pharmaceutical companies including Dr. Reddy's Laboratories, Pfizer, Sun Pharmaceuticals, Abbott India, and others.

Differentiator

Problem solved

Functional benefit

Brands

• Instaraft Syrup: Market-leading raft syrup antacid product.
• Raciraft Syrup

Products and services

• Instaraft Syrup A market-leading raft-formulation antacid syrup that forms a protective floating layer in the stomach to neutralize acid and provide relief from heartburn and acid reflux.
• Raciraft Syrup A specialized raft-formulation antacid syrup similar to Instaraft, designed for acid neutralization and gastroesophageal reflux management.
• Oral Liquids Contract Manufacturing (Syrups & Suspensions) Contract manufacturing of a broad range of oral liquids including syrups, suspensions, cough syrups, raft syrups, and dry syrups in liquid oral dosage forms for various therapeutic applications. Produced for pharmaceutical clients using five state-of-the-art filling and packing lines with capacity of 250,000 bottles per shift and flexible 10 mL to 400 mL fill volumes.
• Sodium Alginate Syrup A specialized antacid liquid formulation using sodium alginate as the active ingredient for acid reflux treatment, manufactured as part of Espi's antacid product portfolio.
• Pharmaceutical Development Services Comprehensive pre-formulation and formulation development services including characterization, flavoring, manufacturing process development, scale-up, and technical transfer for oral delivery pharmaceuticals, with dossiers compiled for regulatory registration in Russia, Africa, and Southeast Asia.
• Analytical Capabilities Services GLP-approved analytical laboratory services including method development, validation, transfer, optimization, and impurity profiling across wet chemistry, instrumentation (HPLC, AAS), and microbiology divisions.
• Stability Studies Services Complete stability testing services including new drug R&D stability, commercial stability, and container/closure stability studies, conducted in state-of-the-art stability chambers with double power backup and central computer monitoring.

Quantifiable outcome

• Production capacity of 70 million bottles annually
• +3 more outcomes

Named customers8 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• SprihsupportingImplementation/ SI/ Consulting PartnerSprih serves as Espi's carbon management and accounting partner, providing expertise, tools, and insights essential for emissions tracking, setting science-based targets, and enhancing environmental reporting accuracy. Their support has been instrumental in aligning with global standards and accelerating progress toward a low-carbon future.

Scale indicators9 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Solara Active Pharma Sciences: Indian pharmaceutical company focused on API and finished formulation manufacturing with CRAMS services; comparable to Espi as an Indian pharma manufacturer offering contract manufacturing services to global clients.
• Strides Pharma: Indian pharmaceutical company with formulation manufacturing capabilities across multiple dosage forms including oral liquids; comparable to Espi in domestic pharma manufacturing serving regulated markets including Africa.
• Piramal Pharma Solutions: India-based global CDMO offering pharmaceutical formulation development and contract manufacturing across multiple dosage forms; comparable to Espi as a domestic Indian CDMO serving major global pharma clients with regulatory-grade manufacturing capabilities.
• Morepen Laboratories: Indian pharmaceutical company with API manufacturing and formulation capabilities including oral liquids; comparable to Espi as a domestic Indian pharma manufacturer with similar therapeutic focus.
• Hikal Limited: Indian CDMO providing API, intermediates, and contract manufacturing services to global pharma and agrochemical companies; comparable to Espi as a domestic Indian contract manufacturer with regulatory-grade capabilities.
• Syngene International: Indian CRO/CDMO providing formulation development, analytical services, and stability studies for global pharma clients; directly comparable to Espi's integrated development and manufacturing service model with similar client profile.
• Granules India: Indian pharmaceutical manufacturer specializing in finished dosages and APIs with strong contract manufacturing services; comparable to Espi in formulation manufacturing serving global pharma clients.
• Jubilant Pharmova: Indian pharmaceutical company offering contract manufacturing services, API production, and formulation development; comparable to Espi as a domestic CDMO with regulatory certifications serving global pharma clients.
• Carbogen Amcis (Dishman): Indian-origin CDMO with global operations providing API and drug product development services; comparable to Espi as a contract manufacturer serving major pharma clients with specialized manufacturing capabilities.

Broad incumbents

• Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with extensive formulation manufacturing capabilities and global distribution; serves as both a major Espi peer in oral liquid manufacturing and as one of Espi's competitor/customers in the broader Indian pharma ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Espi Industries & Chemicals